Literature DB >> 23769926

Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects.

Xiaomeng Wang1, Zhizhong Zhang, Wenhua Liu, Yunyun Xiong, Wen Sun, Xianjun Huang, Yongjun Jiang, Guanzhong Ni, Wenshan Sun, Lulu Zhou, Li Wu, Wusheng Zhu, Hua Li, Xinfeng Liu, Gelin Xu.   

Abstract

Polymorphisms of PDGFRB, MMP-3, TIMP-2, RNF213, TGFB1, Raptor and eNOS genes have been associated with Moyamoya disease (MMD) separately in studies, but their interactions on MMD have never been evaluated in one study. This study enrolled 96 MMD patients and 96 controls to evaluate the contributions and interactions of these polymorphisms on MMD in Chinese Hans. After genotyping, five polymorphisms loci were deemed suitable for analysis, rs3828610 in PDGFRB, rs3025058 in MMP-3, rs8179090 in TIMP-2, rs112735431 and rs148731719 in RNF213. Interactions of different loci on MMD were evaluated by multifactor dimensionality reduction (MDR) method. Significantly higher frequencies of A allele and G/A genotype of rs112735431 in RNF213 were observed in MMD patients compared with controls (P=0.011; P=0.018, respectively). In the dominant model, G/A genotype of rs112735431 was associated with increased risk of MMD (P=0.018). A higher frequency of G allele and G/G genotype of rs148731719 in RNF213 gene in patient than control group (P<0.001; P<0.01, respectively) was also detected. No significant association between MMD and other three loci (P>0.05) was detected. MDR analysis failed to detect any significant interaction among these five loci in the occurrence of MMD (P>0.05), but the combination of three loci (rs112735431 in RNF213, rs3828610 in PDGFRB, rs3025058 in MMP-3) could have the maximum testing accuracy (57.29%) and cross-validation consistency (10/10). The results indicated that RNF213 rs112735431 and rs148731719 may exert a significant influence on MMD occurrence. Compared with this overwhelming effect, the influences of PDGFRB, MMP-3, and TIMP-2 on MMD may be unremarkable in Chinese Hans. There may be no prominent interaction among these five gene polymorphisms on the occurrence of MMD.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetic association studies; MDR; MMD; MMP-3; Moyamoya disease; Multifactor dimensionality reduction; PDGFRB; RNF213; Single nucleotide polymorphisms; TGFB1; TIMP-2; eNOS; endothelial nitric oxide synthase; matrix metalloproteinase-3; multifactor dimensionality reduction; platelet derived growth factor receptor beta; ring finger 213; tissue inhibitors of metalloproteinase-2; transforming growth factor beta 1

Mesh:

Substances:

Year:  2013        PMID: 23769926     DOI: 10.1016/j.gene.2013.05.083

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  15 in total

1.  RNF213 p.Arg4810Lys Heterozygosity in Moyamoya Disease Indicates Early Onset and Bilateral Cerebrovascular Events.

Authors:  Daiichiro Ishigami; Satoru Miyawaki; Hideaki Imai; Masahiro Shimizu; Hiroki Hongo; Shogo Dofuku; Kenta Ohara; Yu Teranishi; Daisuke Shimada; Satoshi Koizumi; Hideaki Ono; Yudai Hirano; Masafumi Segawa; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Transl Stroke Res       Date:  2021-10-30       Impact factor: 6.829

2.  Clinical relevance of peroxisome proliferator-activated receptor-γ gene polymorphisms with sepsis.

Authors:  Yu Liu; Wenhui Wan; Fang Fang; Lei Guo; Yusheng Zhao; Xinghu Zhang; Fang Huang
Journal:  J Clin Lab Anal       Date:  2017-10-21       Impact factor: 2.352

3.  The association between the ring finger protein 213 (RNF213) polymorphisms and moyamoya disease susceptibility: a meta-analysis based on case-control studies.

Authors:  Xun-Sha Sun; Jun Wen; Jiao-Xing Li; Rong Lai; Yu-Fang Wang; Hui-Jiao Liu; Wen-Li Sheng
Journal:  Mol Genet Genomics       Date:  2016-02-05       Impact factor: 3.291

Review 4.  Single Nucleotide Polymorphism in Patients with Moyamoya Disease.

Authors:  Young Seok Park
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

Review 5.  Moyamoya disease and syndromes: from genetics to clinical management.

Authors:  Stéphanie Guey; Elisabeth Tournier-Lasserve; Dominique Hervé; Manoelle Kossorotoff
Journal:  Appl Clin Genet       Date:  2015-02-16

Review 6.  The Pathophysiology of Moyamoya Disease: An Update.

Authors:  Oh Young Bang; Miki Fujimura; Seung-Ki Kim
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

7.  Genetic analysis of RNF213 p.R4810K variant in non-moyamoya intracranial artery stenosis/occlusion disease in a Chinese population.

Authors:  Tong Zhang; Congrong Guo; Xin Liao; Jian Xia; XiaoXiao Wang; Jing Deng; Junxia Yan
Journal:  Environ Health Prev Med       Date:  2017-04-24       Impact factor: 3.674

Review 8.  Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review.

Authors:  Xin Liao; Jing Deng; Wenjie Dai; Tong Zhang; Junxia Yan
Journal:  Environ Health Prev Med       Date:  2017-11-02       Impact factor: 3.674

9.  Construction and Comprehensive Analysis of Dysregulated Long Noncoding RNA-Associated Competing Endogenous RNA Network in Moyamoya Disease.

Authors:  Xuefeng Gu; Dongyang Jiang; Yue Yang; Peng Zhang; Guoqing Wan; Wangxian Gu; Junfeng Shi; Liying Jiang; Bing Chen; Yanjun Zheng; Dingsheng Liu; Sufen Guo; Changlian Lu
Journal:  Comput Math Methods Med       Date:  2020-06-13       Impact factor: 2.238

10.  Serum miRNA signature in Moyamoya disease.

Authors:  Dongwei Dai; Qiong Lu; Qinghai Huang; Pengfei Yang; Bo Hong; Yi Xu; Wenyuan Zhao; Jianmin Liu; Qiang Li
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.